590 documents

Read All
17:38 , Sep 26, 2018 |  BC Innovations  |  Distillery Therapeutics

Neurology

INDICATION: Neurology Mouse models suggest clearing senescent cells could help treat tau-mediated neurodegenerative diseases. In a mouse model of tauopathy expressing mutant human tau in neurons, systemic expression of a fusion human transgene based on...
Read More
22:29 , Sep 21, 2018 |  BioCentury  |  Emerging Company Profile

Aprinoia tackles tau

Aprinoia Therapeutics Inc. is developing a pipeline targeting tauopathies that includes diagnostic imaging tracers, mAbs specific to pathologic tau and small molecules that bind to tau rather than dissociate tau aggregates. “We are going to...
Read More
18:42 , Sep 19, 2018 |  BC Extra  |  Preclinical News

Mayo Clinic team implicates senescent cells in neurodegenerative diseases

Clearing out senescent brain cells could prevent tau-mediated neurodegeneration and cognitive loss, although it's still too early to determine whether the approach can halt or reverse disease progression, according to a...
Read More
18:31 , Aug 31, 2018 |  BC Week In Review  |  Financial News

Arvinas looking to raise $100M in IPO

Protein degradation company Arvinas LLC (New Haven, Conn.) filed to raise up to $100 million in an IPO on NASDAQ underwritten by Goldman Sachs, Citigroup and Piper Jaffray. Arvinas is developing small molecules based on...
Read More
19:59 , Aug 30, 2018 |  BC Extra  |  Financial News

Arvinas looking to raise $100M in IPO

Protein degradation company Arvinas LLC (New Haven, Conn.) filed to raise up to $100 million in an IPO on NASDAQ underwritten by Goldman Sachs, Citigroup and Piper Jaffray. Arvinas is developing small molecules based on...
Read More
15:47 , Aug 23, 2018 |  BC Innovations  |  Distillery Therapeutics

Neurology

INDICATION: Alzheimer’s disease (AD)...
Read More
17:24 , Aug 17, 2018 |  BC Week In Review  |  Company News

BioMotiv, Cure Network developing inhibitory interneuron small molecules

BioMotiv LLC (Cleveland, Ohio) partnered with Cure Network Dolby Acceleration Partners LLC (CNDAP) to develop small molecules that improve the function of inhibitor interneurons to treat neurological disorders, including Dravet syndrome, other epilepsies and Alzheimer’s...
Read More
23:46 , Aug 8, 2018 |  BC Innovations  |  Distillery Therapeutics

Neurology

INDICATION: Alzheimer’s disease (AD); progressive supranuclear palsy (PSP) Patient sample and fly studies suggest PIWIL1 overexpression or inhibiting viral DNA polymerases could help treat AD, PSP and other tauopathies. In postmortem cortex and cerebellum samples...
Read More
23:57 , Jul 26, 2018 |  BC Innovations  |  Targets & Mechanisms

PureTech plumbs the brain

PureTech Health plc is backing a new way of thinking about Alzheimer’s disease that positions it primarily as a problem of poor drainage, building on the recent discovery of lymphatic vessels in the brain by...
Read More
16:11 , Jul 24, 2018 |  BC Innovations  |  Distillery Therapeutics

Neurology; autoimmune disease

INDICATION: Alzheimer’s disease (AD); multiple sclerosis (MS); rheumatoid arthritis (RA) Patient sample,...
Read More